Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Heliyon ; 9(1): e12698, 2023 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-36632095

RESUMO

Healthy diet is vital to cellular health. The human body succumbs to numerous diseases which afflict severe economic and psychological burdens on the patient and family. Oxidative stress is a possible crucial regulator of various pathologies, including type 2 diabetes and neurodegenerative diseases. It generates reactive oxygen species (ROS) that trigger the dysregulation of essential cellular functions, ultimately affecting cellular health and homeostasis. However, lower levels of ROS can be advantageous and are implicated in a variety of signaling pathways. Due to this dichotomy, the terms oxidative "eustress," which refers to a good oxidative event, and "distress," which can be hazardous, have developed. ROS affects multiple signaling pathways, leading to compromised insulin secretion, insulin resistance, and ß-cell dysfunction in diabetes. ROS is also associated with increased mitochondrial dysfunction and neuroinflammation, aggravating neurodegenerative conditions in the body, particularly with age. Treatment includes drugs/therapies often associated with dependence, side effects including non-selectivity, and possible toxicity, particularly in the long run. It is imperative to explore alternative medicines as an adjunct therapy, utilizing natural remedies/resources to avoid all the possible harms. Antioxidants are vital components of our body that fight disease by reducing oxidative stress or nullifying the excess toxic free radicals produced under various pathological conditions. In this review, we focus on the antioxidant effects of components of dietary foods such as tea, coffee, wine, oils, and honey and the role and mechanism of action of these antioxidants in alleviating type 2 diabetes and neurodegenerative disorders. We aim to provide information about possible alternatives to drug treatments used alone or combined to reduce drug intake and encourage the consumption of natural ingredients at doses adequate to promote health and combat pathologies while reducing unwanted risks and side effects.

2.
Molecules ; 27(13)2022 Jun 23.
Artigo em Inglês | MEDLINE | ID: mdl-35807283

RESUMO

Obesity is a chronic disease with increasing cases among children and adolescents. Melanocortin 4 receptor (MC4R) is a G protein-coupled transporter involved in solute transport, enabling it to maintain cellular homeostasis. MC4R mutations are associated with early-onset severe obesity, and the identification of potential pathological variants is crucial for the clinical management of patients with obesity. A number of mutations have been reported in MC4R that are responsible for causing obesity and related complications. Delineating these mutations and analyzing their effect on MC4R's structure will help in the clinical intervention of the disease condition as well as designing potential drugs against it. Sequence-based pathogenicity and structure-based protein stability analyses were conducted on naturally occurring variants. We used computational tools to analyze the conservation of these mutations on MC4R's structure to map the structural variations. Detailed structural analyses were carried out for the active site mutations (i.e., D122N, D126Y, and S188L) and their influence on the binding of calcium and the agonist or antagonist. We performed molecular dynamics (MD) simulations of the wild-type and selected mutations to delineate the conformational changes, which provided us with possible reasons for MC4R's instability in these mutations. This study provides insight into the potential direction toward understanding the molecular basis of MC4R dysfunction in disease progression and obesity.


Assuntos
Obesidade , Receptor Tipo 4 de Melanocortina , Adolescente , Sequência de Aminoácidos , Criança , Humanos , Mutação , Obesidade/genética , Obesidade/metabolismo , Conformação Proteica , Receptor Tipo 4 de Melanocortina/química , Receptor Tipo 4 de Melanocortina/genética , Relação Estrutura-Atividade
3.
Molecules ; 27(3)2022 Feb 07.
Artigo em Inglês | MEDLINE | ID: mdl-35164370

RESUMO

Fibrin-based systems offer promises in drug and gene delivery as well as tissue engineering. We established earlier a fibrin-based plasma beads (PB) system as an efficient carrier of drugs and antigens. In the present work, attempts were made to further improve its therapeutic efficacy exploiting innovative ideas, including the use of plasma alginate composite matrices, proteolytic inhibitors, cross linkers, and dual entrapment in various liposomal formulations. In vitro efficacy of the different formulations was examined. Pharmacokinetics of the formulations encapsulating Amphotericin B (AmpB), an antifungal compound, were investigated in Swiss albino mice. While administration of the free AmpB led to its rapid elimination (<72 h), PB/liposome-PB systems were significantly effective in sustaining AmpB release in the circulation (>144 h) and its gradual accumulation in the vital organs, also compared to the liposomal formulations alone. Interestingly, the slow release of AmpB from PB was unusual compared to other small molecules in our earlier findings, suggesting strong interaction with plasma proteins. Molecular interaction studies of bovine serum albumin constituting approximately 60% of plasma with AmpB using isothermal titration calorimetry and in silico docking verify these interactions, explaining the slow release of AmpB entrapped in PB alone. The above findings suggest that PB/liposome-PB could be used as safe and effective delivery systems to combat fungal infections in humans.


Assuntos
Anfotericina B/farmacologia , Antifúngicos/farmacologia , Sistemas de Liberação de Medicamentos , Fungos/efeitos dos fármacos , Lipossomos/administração & dosagem , Micoses/tratamento farmacológico , Plasma/química , Alginatos/química , Anfotericina B/química , Animais , Antifúngicos/química , Feminino , Lipossomos/química , Camundongos , Coelhos
4.
Diabetes Obes Metab ; 24(4): 583-598, 2022 04.
Artigo em Inglês | MEDLINE | ID: mdl-34882941

RESUMO

The melanocortin-4 receptor (MC4R) has been critically investigated for the past two decades, and novel findings regarding MC4R signalling and its potential exploitation in weight loss therapy have lately been emphasized. An association between MC4R and obesity is well established, with disease-causing mutations affecting 1% to 6% of obese patients. More than 200 MC4R variants have been reported, although conflicting results as to their effects have been found in different cohorts. Most notably, some MC4R gain-of-function variants seem to rescue obesity and related complications via specific pathways such as beta-arrestin (ß-arrestin) recruitment. Broadly speaking, however, dysfunctional MC4R dysregulates satiety and induces hyperphagia. The picture at the mechanistic level is complicated as, in addition to the canonical G stimulatory pathway, the ß-arrestin signalling pathway and ions (particularly calcium) seem to interact with MC4R signalling to contribute to or alleviate obesity pathogenesis. Thus, the overall complexity of the MC4R signalling spectra has broadened considerably, indicating there is great potential for the development of new drugs to manage obesity and its related complications. Alpha-melanocyte-stimulating hormone is the major endogenous MC4R agonist, but structure-based ligand discovery studies have identified possible superior and selective agonists that can improve MC4R function. However, some of these agonists characterized in vitro and in vivo confer adverse effects in patients, as demonstrated in clinical trials. In this review, we provide a comprehensive insight into the genetics, function and regulation of MC4R and its contribution to obesity. We also outline new approaches in drug development and emerging drug candidates to treat obesity.


Assuntos
Obesidade , Receptor Tipo 4 de Melanocortina , Desenvolvimento de Medicamentos , Homeostase , Humanos , Obesidade/tratamento farmacológico , Obesidade/genética , Obesidade/metabolismo , Receptor Tipo 4 de Melanocortina/genética , Receptor Tipo 4 de Melanocortina/metabolismo , alfa-MSH/metabolismo , alfa-MSH/farmacologia , alfa-MSH/uso terapêutico
5.
Int J Biol Macromol ; 190: 44-55, 2021 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-34480905

RESUMO

With varying clinical symptoms, most neurodegenerative diseases are associated with abnormal loss of neurons. They share the same common pathogenic mechanisms involving misfolding and aggregation, and these visible aggregates of proteins are deposited in the central nervous system. Amyloid formation is thought to arise from partial unfolding of misfolded proteins leading to the exposure of hydrophobic surfaces, which interact with other similar structures and give rise to form dimers, oligomers, protofibrils, and eventually mature fibril aggregates. Accumulating evidence indicates that amyloid oligomers, not amyloid fibrils, are the most toxic species that causes Alzheimer's disease (AD) and Parkinson's disease (PD). AD has recently been recognized as the 'twenty-first century plague', with an incident rate of 1% at 60 years of age, which then doubles every fifth year. Currently, 5.3 million people in the US are afflicted with this disease, and the number of cases is expected to rise to 13.5 million by 2050. PD, a disorder of the brain, is the second most common form of dementia, characterized by difficulty in walking and movement. Keeping the above views in mind, in this review we have focused on the roles of amyloid in neurodegenerative diseases including AD and PD, the involvement of amyloid in mitochondrial dysfunction leading to neurodegeneration, are also considered in the review.


Assuntos
Doença de Alzheimer/metabolismo , Amiloide/metabolismo , Doença de Parkinson/metabolismo , Amiloide/química , Animais , Humanos , Mitocôndrias/patologia , Degeneração Neural/patologia
6.
Int J Biol Macromol ; 186: 580-590, 2021 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-34271045

RESUMO

Protein misfolding and aggregation can be induced by a wide variety of factors, such as dominant disease-associated mutations, changes in the environmental conditions (pH, temperature, ionic strength, protein concentration, exposure to transition metal ions, exposure to toxins, posttranslational modifications including glycation, phosphorylation, and sulfation). Misfolded intermediates interact with similar intermediates and progressively form dimers, oligomers, protofibrils, and fibrils. In amyloidoses, fibrillar aggregates are deposited in the tissues either as intracellular inclusion or extracellular plaques (amyloid). When such proteinaceous deposit occurs in the neuronal cells, it initiates degeneration of neurons and consequently resulting in the manifestation of various neurodegenerative diseases. Several different types of molecules have been designed and tested both in vitro and in vivo to evaluate their anti-amyloidogenic efficacies. For instance, the native structure of a protein associated with amyloidosis could be stabilized by ligands, antibodies could be used to remove plaques, oligomer-specific antibody A11 could be used to remove oligomers, or prefibrillar aggregates could be removed by affibodies. Keeping the above views in mind, in this review we have discussed protein misfolding and aggregation, mechanisms of protein aggregation, factors responsible for aggregations, and strategies for aggregation inhibition.


Assuntos
Doença de Alzheimer/tratamento farmacológico , Proteínas Amiloidogênicas/metabolismo , Amiloidose/tratamento farmacológico , Nanopartículas , Agregados Proteicos , Agregação Patológica de Proteínas , Anticorpos de Domínio Único/farmacologia , Doença de Alzheimer/metabolismo , Doença de Alzheimer/patologia , Proteínas Amiloidogênicas/antagonistas & inibidores , Amiloidose/metabolismo , Amiloidose/patologia , Animais , Humanos , Conformação Proteica , Dobramento de Proteína
7.
Pharmacol Res ; 167: 105544, 2021 05.
Artigo em Inglês | MEDLINE | ID: mdl-33722711

RESUMO

Cancer is one of the major global health problems, responsible for the second-highest number of deaths. The genetic and epigenetic changes in the oncogenes or tumor suppressor genes alter the regulatory pathways leading to its onset and progression. Conventional methods are used in appropriate combinations for the treatment. Surgery effectively treats localized tumors; however, it fails to treat metastatic tumors, leading to a spread in other organs, causing a high recurrence rate and death. Among the different strategies, the nanocarriers-based approach is highly sought for, but its nonspecific delivery can cause a profound side effect on healthy cells. Targeted nanomedicine has the advantage of targeting cancer cells specifically by interacting with the receptors overexpressed on their surface, overcoming its non-specificity to target healthy cells. Nanocarriers prepared from biodegradable and biocompatible materials are decorated with different ligands by encapsulating therapeutic or diagnostic agents or both to target cancer cells overexpressing the receptors. Scientists are now utilizing a theranostic approach to simultaneously evaluate nanocarrier bio-distribution and its effect on the treatment regime. Herein, we have summarized the recent 5-year efforts in the development of the ligands decorated biodegradable nanocarriers, as a targeted nanomedicine approach, which has been highly promising in the treatment of cancer.


Assuntos
Antineoplásicos/administração & dosagem , Portadores de Fármacos/química , Sistemas de Liberação de Medicamentos , Nanoestruturas/química , Neoplasias/tratamento farmacológico , Animais , Antineoplásicos/farmacocinética , Antineoplásicos/uso terapêutico , Sistemas de Liberação de Medicamentos/métodos , Humanos , Ligantes , Nanomedicina/métodos
8.
Int J Biol Macromol ; 130: 515-526, 2019 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-30826404

RESUMO

Alzheimer's disease (AD) is one of the most common age-related diseases that occurs because of the deposition of amyloid fibrils in a form of extracellular plaques containing ß-amyloid peptide (Aß) and tangles are found as intracellular deposit in the brain made up of twisted strands of aggregated microtubule binding protein. Scores of small molecule inhibitors have been designed for the treatment of AD. However some of these drugs cannot pass through the brain-blood-barrier (BBB). To overcome this problem, various nanoparticles (NPs) or nanomedicines (NMs) have been synthesized. These nanoparticles exploit the existing physiological mechanisms of passing through the BBB, including receptor- and adsorptive-mediated transcytosis that facilitate the transcellular transport of nanoparticle from the blood to the brain. During the last decades, varieties of nanoparticles that differ in the composition have been developed, and they have the potential application in the diagnostics and therapy of AD. The most common NP formulations that have major impact in the diagnosis and therapy of AD include polymeric NPs (PPs), gold NPs, gadolinium NPs, selenium NPs, protein-based NPs, polysaccharide-based NPs, etc. The goal of this review is to provide discussion of the application of different types of NP formulations in the diagnosis and therapy of AD.


Assuntos
Doença de Alzheimer/diagnóstico , Doença de Alzheimer/terapia , Composição de Medicamentos , Nanopartículas , Nanomedicina Teranóstica , Doença de Alzheimer/etiologia , Doença de Alzheimer/metabolismo , Animais , Portadores de Fármacos/química , Sistemas de Liberação de Medicamentos , Hormônios/administração & dosagem , Hormônios/uso terapêutico , Humanos , Nanopartículas Metálicas/química , Metais/química , Nanopartículas/química , Polímeros/química , Nanomedicina Teranóstica/métodos
9.
Biomed Pharmacother ; 107: 34-43, 2018 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-30077836

RESUMO

Liposomes have established themselves as great pharmaceutical carriers over the past three decades. These phospholipid vesicular systems have undergone great technical advances including remote drug loading, targeted delivery, and combinatorial drug therapy. Ionic gradient liposomes (IGL) necessitates active loading of the drug in preformed vesicles exhibiting a transmembrane pH or ion gradient, with a low intra liposome pH (∼ 4-5), and a high outside pH (∼7-8). It allows high drug encapsulation and prolonged release, particularly for amphipathic weak acids and weak bases. Most local anesthetics (Bupivacaine, Ropivacaine, Tetracaine, and others) have a pka in the range of 7-9, which makes them ideal candidates for their entrapment in IGL. The same is true for most anthracyclines which have great anti-tumor properties (Doxorubicin, Daunorubicin, Idarubicin, and others). Many FDA approved liposomal drugs utilise ion gradient for their encapsulation. Considering their immense utility, we summarize here in this review, the recent contributions made by various research groups utilizing IGL, to accentuate the development of these carriers in drug delivery. This would possibly be helpful in carrying new investigations and further contributions in the optimization and advancements of new drugs for better therapeutics.


Assuntos
Anestésicos Locais/farmacologia , Antineoplásicos/farmacologia , Preparações de Ação Retardada/farmacologia , Íons , Lipossomos
10.
Curr Protein Pept Sci ; 19(9): 858-875, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-28762306

RESUMO

Protein homeostasis (proteostasis) is achieved by the interplay among various components and pathways inside a cell. Dysfunction in proteostasis leads to protein misfolding and aggregation which is ubiquitously associated with many neurodegenerative disorders, although the exact role of these aggregate in the pathogenesis remains unknown. Many neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and others are characterized by the conversion of specific protein aggregates into protein inclusions and/or plaques in degenerating brains. Apart from the conventional disease specific proteins, such as amyloid-ß, α - synuclein, huntingtin protein, and prions that are known to aggregate, a number of other proteins play a vital role in aggravating the disease condition. In this review, we discuss the disease etiology, mechanism, the role of various pathways, molecular machinery including molecular chaperones, protein degradation pathways, and the active formation of inclusions in various neurodegenerative diseases. We also highlight the approaches, strategies, and methods that have been used for the treatment of these complex diseases over the years and the efforts that have potential in the near future.


Assuntos
Doenças Neurodegenerativas/terapia , Proteínas/metabolismo , Proteômica/métodos , Desenho de Fármacos , Humanos , Chaperonas Moleculares/metabolismo , Terapia de Alvo Molecular , Doenças Neurodegenerativas/etiologia , Doenças Neurodegenerativas/metabolismo , Dobramento de Proteína , Multimerização Proteica , Proteínas/antagonistas & inibidores , Proteólise , Proteostase
11.
Int J Biol Macromol ; 109: 1164-1173, 2018 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-29157912

RESUMO

Classically, ankyrin repeat (ANK) proteins are built from tandems of two or more repeats and form curved solenoid structures that are associated with protein-protein interactions. These are short, widespread structural motif of around 33 amino acids repeats in tandem, having a canonical helix-loop-helix fold, found individually or in combination with other domains. The multiplicity of structural pattern enables it to form assemblies of diverse sizes, required for their abilities to confer multiple binding and structural roles of proteins. Three-dimensional structures of these repeats determined to date reveal a degree of structural variability that translates into the considerable functional versatility of this protein superfamily. Recent work on the ANK has proposed novel structural information, especially protein-lipid, protein-sugar and protein-protein interaction. Self-assembly of these repeats was also shown to prevent the associated protein in forming filaments. In this review, we summarize the latest findings and how the new structural information has increased our understanding of the structural determinants of ANK proteins. We discussed latest findings on how these proteins participate in various interactions to diversify the ANK roles in numerous biological processes, and explored the emerging and evolving field of designer ankyrins and its framework for protein engineering emphasizing on biotechnological applications.


Assuntos
Repetição de Anquirina , Proteínas/química , Proteínas/metabolismo , Biotecnologia , Glicoproteínas/química , Glicoproteínas/metabolismo , Lipídeos/química , Lipoproteínas/química , Lipoproteínas/metabolismo , Modelos Moleculares , Ligação Proteica , Mapeamento de Interação de Proteínas , Multimerização Proteica , Relação Estrutura-Atividade , Açúcares/química , Açúcares/metabolismo
12.
J Drug Target ; 26(2): 162-171, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-28671003

RESUMO

Fibrin-based polymeric systems have now emerged as efficient carriers of drugs, growth factors, genes, and cells. Earlier, we have reported fibrin-based plasma beads (PB), prepared from clotted whole plasma, as an efficient system for the controlled release of entrapped therapeutics. In the present study, we investigate the dual entrapment in erythrocytes and PB, as potential particulate antigen delivery system in rabbit and mice, with yeast invertase as the model antigen. Preparations used for immunisation include- invertase entrapped in erythrocytes, the same further entrapped in PB, and crosslinked with glutaraldehyde. While route of administration of the antigen only moderately affected the antibody titres, strategies slowing its release from PB increased the antibody titres remarkably, especially after a booster. Entrapment of erythrocytes entrapped antigen in the PB and further crosslinking with glutaraldehyde also resulted in significant alterations of IgG1/IgG2a ratio, indicating a shift towards humoral response. The elicited immune response was more marked in rabbits as compared to that in mice. Considering the well-known toxicity of the adjuvant, comparable antibody titres induced by the erythrocyte-plasma bead system was encouraging in the induction of humoral immunity.


Assuntos
Micropartículas Derivadas de Células/imunologia , Eritrócitos , Plasma/química , Animais , Antígenos/química , Antígenos/imunologia , Antígenos de Fungos/imunologia , Micropartículas Derivadas de Células/química , Sistemas de Liberação de Medicamentos , Camundongos , Camundongos Endogâmicos BALB C , Microesferas , beta-Frutofuranosidase/imunologia
13.
Eur J Med Chem ; 114: 41-58, 2016 May 23.
Artigo em Inglês | MEDLINE | ID: mdl-26974374

RESUMO

Protein misfolding is one of the leading causes of amyloidoses. Protein misfolding occurs from changes in environmental conditions and host of other factors, including errors in post-translational modifications, increase in the rate of degradation, error in trafficking, loss of binding partners and oxidative damage. Misfolding gives rise to the formation of partially unfolded or misfolded intermediates, which have exposed hydrophobic residues and interact with complementary intermediates to form oligomers and consequently protofibrils and fibrils. The amyloid fibrils accumulate as amyloid deposits in the brain and central nervous system in Alzheimer's disease (AD), Prion disease and Parkinson's disease (PD). Initial studies have shown that amyloid fibrils were the main culprit behind toxicity that cause neurodegenerative diseases. However, attention shifted to the cytotoxicity of amyloid fibril precursors, notably amyloid oligomers, which are the major cause of toxicity. The mechanism of toxicity triggered by amyloid oligomers remains elusive. In this review, we have focused on the current knowledge of the structures of different aggregated states, including amyloid fibril, protofibrils, annular aggregates and oligomers. Based on the studies on the mechanism of toxicities, we hypothesize two major possible mechanisms of toxicities instigated by oligomers of Aß (amyloid beta), PrP (prion protein) (106-126), and α-Syn (alpha-synuclein) including direct formation of ion channels and neuron membrane disruption by the increase in membrane conductance or leakage in the presence of small globulomers to large prefibrillar assemblies. Finally, we have discussed various novel innovative approaches that target amyloid oligomers in Alzheimer's diseases, Prion disease and Parkinson's disease.


Assuntos
Doença de Alzheimer/tratamento farmacológico , Amiloide/química , Amiloide/toxicidade , Doença de Parkinson/tratamento farmacológico , Doenças Priônicas/tratamento farmacológico , Doença de Alzheimer/metabolismo , Doença de Alzheimer/patologia , Amiloide/metabolismo , Animais , Humanos , Estrutura Molecular , Doença de Parkinson/metabolismo , Doença de Parkinson/patologia , Doenças Priônicas/metabolismo , Doenças Priônicas/patologia , Conformação Proteica
14.
Int J Biol Macromol ; 81: 121-36, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-26231328

RESUMO

Fibrin sealants, that have been employed for over a century by surgeons to stop post surgery bleeding, are finding novel applications in the controlled delivery of antibiotics and several other therapeutics. Fibrinogen can be easily purified from blood plasma and converted by thrombolysis to fibrin that undergoes spontaneous aggregation to form insoluble clot. During the gelling, fibrin can be formulated into films, clots, threads, microbeads, nanoconstructs and nanoparticles. Whole plasma clots in the form of beads and microparticles can also be prepared by activating endogenous thrombin, for possible drug delivery. Fibrin formulations offer remarkable scope for controlling the porosity as well as in vivo degradability and hence the release of the associated therapeutics. Binding/covalent-linking of therapeutics to the fibrin matrix, crosslinking of the matrix with bifunctional reagents and coentrapment of protease inhibitors have been successful in regulating both in vitro and in vivo release of the therapeutics. The release rates can also be remarkably lowered by preentrapment of therapeutics in insoluble particles like liposomes or by anchoring them to the matrix via molecules that bind them as well as fibrin.


Assuntos
Portadores de Fármacos/química , Sistemas de Liberação de Medicamentos , Fibrina/química , Animais , Adesivo Tecidual de Fibrina/química , Humanos , Plasma/química
15.
Int J Biol Macromol ; 81: 100-11, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-26231333

RESUMO

The development of prophylactic anti-candidal vaccine comprising the Candida albicans cytosolic proteins (Cp) as antigen and plasma beads (PB) prepared from plasma as sustained delivery system, is described. The immune-prophylactic potential of various PBs-based dual antigen delivery systems, co-entrapping Cp pre-entrapped in PLGA microspheres were tested in the murine model. Induction of cell mediated immunity was measured by assaying DTH and NO production as well as in vitro proliferation of lymphocytes derived from the immunized animals. Expression of surface markers on APCs (CD80, CD86) and T-cells (CD4+, CD8+) was also evaluated. Humoral immune response was studied by measuring circulating anti-Cp antibodies and their subclasses. When the prophylactic efficacy of the vaccines was tested in mice challenged with virulent C. albicans, the PB-based formulation (PB-PLGA-Cp vaccine) was found to be most effective in the generation of desirable immune response, in terms of suppression of fungal load and facilitating the survival of the immunized animals.


Assuntos
Antígenos de Fungos/imunologia , Materiais Biocompatíveis/química , Candida/imunologia , Candidíase/prevenção & controle , Vacinas Fúngicas/imunologia , Plasma/química , Animais , Células Apresentadoras de Antígenos/imunologia , Células Apresentadoras de Antígenos/metabolismo , Biopolímeros/química , Candidíase/imunologia , Candidíase/microbiologia , Citocinas/biossíntese , Modelos Animais de Doenças , Feminino , Fibrina/química , Imunidade Celular , Imunidade Humoral , Imunização , Imunoglobulina G/imunologia , Ácido Láctico/química , Ativação Linfocitária/imunologia , Camundongos , Óxido Nítrico/biossíntese , Tamanho da Partícula , Ácido Poliglicólico/química , Copolímero de Ácido Poliláctico e Ácido Poliglicólico , Subpopulações de Linfócitos T/imunologia , Subpopulações de Linfócitos T/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...